Chemours Company (the) · NYSE:CC

Chemours Company (the) — Q2 2025 Earnings Presentation

28 slides from Chemours Company (the)'s earnings presentation, Aug 6, 2025

  1. Slide 1: Second Quarter 2025 Earnings Presentation

    Second Quarter 2025 Earnings Presentation August 6, 2025

  2. Slide 2: Safe Harbor Statement and Other Matters

    Safe Harbor Statement and Other Matters This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current exp

  3. Slide 3: Second Quarter 2025 Highlights

    Second Quarter 2025 Highlights Generated $1.6B in Net Sales and $253M in Adjusted EBITDA Achieved 65% YoY Net Sales growth for Opteon Refrigerants in TSS, reflecting continued strong adoption Announced a settlement with the State of New Jersey to comprehensively resolve all environmental claims incl

  4. Slide 4: Second Quarter 2025 Financial Summary

    Second Quarter 2025 Financial Summary ($ in millions unless otherwise noted; excludes per share amounts) 2Q25 2Q24 5 Y-o-Y ∆ 1Q25 Q-o-Q ∆ Net Sales $1,615 $1,554 $61 $1,368 $247 Net (Loss) / Income 1 ($381) $60 ($441) ($4) ($377) Adj. Net Income 2 $87 $58 $29 $19 $68 EPS 3 ($2.54) $0.39 ($2.93) ($0.

  5. Slide 5: Adjusted EBITDA Bridge: 2Q25 versus 2Q24

    Adjusted EBITDA Bridge: 2Q25 versus 2Q24 ($ in millions) $7 $34 ($9) $14 $253 $207 2Q24 5 Price Volume Cost/Other Currency 2Q25 Price Impacts: $14 million due to higher pricing in TSS primarily driven by stronger Opteon Refrigerant blends aftermarket demand and strong pricing in APM, in connection w

  6. Slide 6: Quarterly Segment Summary

    Quarterly Segment Summary ($ in millions unless otherwise noted) Net Sales 5 TSS TT APM $533 $519 $597 $707 $677 $657 $394 $345 $346 2Q23 2Q24 2Q25 2Q23 2Q24 2Q25 2Q23 2Q24 2Q25 Adjusted EBITDA and Margin 5 (%) TSS TT APM $214 $160 $207 $87 $83 $47 $81 $45 $50 2Q23 2Q24 2Q25 2Q23 2Q24 2Q25 2Q23 2Q24

  7. Slide 7: Liquidity Position as of June 30, 2025

    Liquidity Position as of June 30, 2025 ($ in millions unless otherwise noted) Total Liquidity 9 $1.5B Gross Debt $4.2B Net Debt 10 $3.7B TTM Net Leverage 11 4.7x $553 $514 $51 Restricted $50 Restricted ($43) ($13) $2 $93 $464 $502 Unrestricted Unrestricted 6 7 8 6 1Q25 Cash Balance Operating Cash Fl

  8. Slide 8: Strategic Progress: Pathway to Thrive

    Strategic Progress: Pathway to Thrive 8

  9. Slide 9: Our Corporate Strategy: Pathway to Thrive – Pillars for Success

    Our Corporate Strategy: “Pathway to Thrive” Pillars for Success PATHWAY TO THRIVE Operational Enabling Portfolio Strengthening Excellence Growth Management the Long Term ❑ Manufacturing excellence as ❑ Investing smartly in selected ❑ Holistic portfolio analysis ❑ Measurable progress on a basis for s

  10. Slide 10: Our Corporate Strategy: Pathway to Thrive – Progress Achieved to Date

    Our Corporate Strategy: “Pathway to Thrive” Progress Achieved to Date PATHWAY TO THRIVE Operational Enabling Portfolio Strengthening Excellence Growth Management the Long Term ✓ Notable progress against the $125M ✓ 65% YoY growth in Opteon ✓ Progressed APM European asset ✓ Agreed to a proposed Judic

  11. Slide 11: Strengthening the Long-Term: Resolving Legacy Liabilities

    Strengthening the Long-Term: Resolving Legacy Liabilities Announced a Settlement with the State of New Jersey to Comprehensively Resolve Environmental Claims Including PFAS Key Considerations Resolves all environmental claims, including those related to PFAS, across four current and former operating

  12. Slide 12: Strengthening the Long-Term: Continued Progress

    Strengthening the Long-Term: Resolving Legacy Liabilities Continued Progress 2017: January 2021: June 2023: December 2024: Priorities for Resolving 1st Ohio MDL MOU with Corteva, EID, DuPont and U.S. Public Water System 3rd Ohio MDL Settlement Chemours on PFAS Liabilities: Class Action Settlement Se

  13. Slide 13: Q3 and Full Year Guidance

    in Q3 and Full Year Guidance 13

  14. Slide 14: Third Quarter 2025 Guidance

    Third Quarter 2025 Guidance Sequential Business Outlook: ($ in millions)  Consolidated 3Q25 Net Sales and Adjusted EBITDA Outlook o Net Sales: Expected to decrease 4-6% sequentially o Adjusted EBITDA: Expected to range between $175 million and $195 million Net Sales o Corporate Expenses as an offse

  15. Slide 15: Full Year 2025 Outlook

    Full Year 2025 Outlook12 Net Key Business Factors and Assumptions Sales $5.9B - $6.0B  High end of Adjusted EBITDA range anticipates an improving demand environment for TT and TSS, paired with operational impacts from the Q3 outage to APM being more limited than expected Adjusted  Low end of Adjus

  16. Slide 16: Appendix

    Appendix

  17. Slide 17: TSS Segment Net Sales and Adjusted EBITDA (Unaudited)

    TSS Segment Net Sales and Adjusted EBITDA (Unaudited)5 ($ in millions) ($ in millions) % of total Net Sales $597 $519 FP&O 16% FP&O $58 23% $20 Freon Refrigerants Freon 21% Refrigerants Q2 24 % total Q2 25 % total 33% refrigerants: refrigerants: Freon = 43% Freon = 25% Opteon Opteon Opteon = 57% Opt

  18. Slide 18: TT Segment Net Sales and Adjusted EBITDA (Unaudited)

    TT Segment Net Sales and Adjusted EBITDA (Unaudited)5 ($ in millions) ($ in millions) $677 $657 ($21) $1 $83 $47 2Q24 Price/Currency Volume 2Q25 2Q24 Price/Currency Volume Cost/Other 2Q25 Net Sales: The year-over-year decrease was primarily driven by a 4% decrease in price globally, partially offset

  19. Slide 19: APM Segment Net Sales and Adjusted EBITDA (Unaudited)

    APM Segment Net Sales and Adjusted EBITDA (Unaudited)5 ($ in millions) ($ in millions) % of total Net Sales $345 $346 Performance $22 ($21) Performance Solutions Solutions 39% 38% Advanced Advanced Materials Materials 61% 62% $45 $50 2Q24 Price/Currency Volume 2Q25 2Q24 Price/Currency Volume Cost/Ot

  20. Slide 20: Segment Net Sales (Unaudited)

    Segment Net Sales (Unaudited)5 ($ in millions) 2022 2023 2024 2025 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Net sales by product group and segment OpteonTM refrigerants $ 143 $ 182 $ 150 $ 122 $ 195 $ 200 $ 170 $ 145 $ 200 $ 227 $ 205 $ 178 $ 279 $ 375 FreonTM refrigerants 197 241 177 135 185 226 1

  21. Slide 21: Segment Net Sales by Region (Unaudited)

    Segment Net Sales by Region (Unaudited)5 2023 2024 2025 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Net sales by geographic region North America: Thermal & Specialized Solutions $ 292 $ 319 $ 258 $ 207 $ 271 $ 308 $ 256 $ 194 $ 233 $ 336 Titanium Technologies 262 277 273 242 246 274 270 236 267 282 Advanced Perfo

  22. Slide 22: Actual and Projected Disruption & Investment Costs (Unaudited)

    Actual and Projected Disruption & Investment Costs (Unaudited) 22

  23. Slide 23: Segment Net Sales and Adjusted EBITDA (Unaudited)

    Segment Net Sales and Adjusted EBITDA (Unaudited)5 5 Refer to footnote provided on the preceding slides. 23

  24. Slide 24: GAAP Net (Loss) Income to Adjusted Net Income and Adjusted EBITDA Reconciliation (Page 1/2)

    GAAP Net (Loss) Income Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited) GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio5 (Page 1/2) ($ in millions except per share amounts) Three Months Ended Three Months Ended Twelve Months Ended June 30, March 3

  25. Slide 25: GAAP Net (Loss) Income to Adjusted Net Income and Adjusted EBITDA Reconciliation (Page 2/2)

    GAAP Net (Loss) Income Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited) GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio5 (Page 2/2) ($ in millions except per share amounts) Three Months Ended Three Months Ended Twelve Months Ended June 30, March 3

  26. Slide 26: GAAP Operating Cash Flow to Free Cash Flow and Conversion Reconciliation

    GAAP Cash Flow Provided by Operating Activities to Free Cash Flows and Free Cash Flow Conversion Reconciliation ($ in millions) Three Months Ended Six Months Ended June 30, March 31, June 30, 2025 2024 2025 2025 2024 Cash flows provided by (used for) operating activities (1) $ 93 $ (620) $ (112) $ (

  27. Slide 27: 2025 Estimated GAAP Net Income to Estimated Adjusted Net Income and EBITDA

    2025 Estimated GAAP Net Income Attributable to Chemours to Estimated Adjusted Net Income, Estimated Adjusted EBITDA(*) (In millions except per share amounts) (Estimated) Year Ending December 31, 2025 Low High Net loss attributable to Chemours $ (336) $ (300) Restructuring, transaction, and other cos

  28. Slide 28: ® 2025 CHEMOURS. ALL RIGHT RESERVED

    ® 2025 CHEMOURS. ALL RIGHT RESERVED

Chemours Company (The) — Q2 2025 Earnings Presentation on 6ix